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ABSTRACT
Removal of ribonucleotides (rNMPs) incorporated
into the genome by the ribonucleotide excision re-
pair (RER) is essential to avoid genetic instability. In
eukaryotes, the RNaseH2 is the only known enzyme
able to incise 5′ of the rNMP, starting the RER pro-
cess, which is subsequently carried out by replica-
tive DNA polymerases (Pols)  or , together with
Flap endonuclease 1 (Fen-1) and DNA ligase 1. Here,
we show that the DEAD-box RNA helicase DDX3X
has RNaseH2-like activity and can support fully re-
constituted in vitro RER reactions, not only with Pol
 but also with the repair Pols  and . Silencing of
DDX3X causes accumulation of rNMPs in the cellu-
lar genome. These results support the existence of
alternative RER pathways conferring high flexibility




Compelling experimental evidence accumulating in the last
years, led to the realization that the most abundant type
of endogenous DNA damage in mammalian cells is rep-
resented by the >1 million ribonucleotides (rNMPs) erro-
neously incorporated into the genome at each round of
replication. Unexpectedly, the number of erroneously in-
corporated rNMPs is even higher than the well-known ox-
idized bases or cyclobutane pyrimidine dimers (1). rNMPs
misincorporation leads to deleterious consequences: their
presence into the genome makes the sugar-phosphate back-
bone ∼100 000- times more prone to hydrolysis due to the
presence of the 2′-OH in their ribose ring. This might lead
to DNA breaks and replication fork arrest. In addition,
the structural modification imposed by the presence of rN-
MPs, could affect protein-DNA interactions, nucleosome
structure and the activity of DNA-processing enzymes such
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as topoisomerases and ligases (2). Indeed, accumulation of
rNMPs in the genome has been linked to increased muta-
genesis and genetic instability in eukaryotic cells (3).
The only enzymes known so far able to remove rN-
MPs into a DNA stretch are RNaseH-type enzymes. There
are two main classes of RNaseH enzymes: RNaseH1 and
RNaseH2 that display significant differences in their enzy-
matic properties. RNaseH1 normally removes DNA:RNA
hybrids (or R-loops) of at least three-four residues. In con-
trast, RNaseH2 is the only enzyme able to process single
rNMPs into a dsDNA context cleaving on the 5′ side of
them and promoting an error-free and specialized repair
pathway called ribonucleotide excision repair (RER) (4).
After RNaseH2-dependent cleavage at the 5′-side of the
rNMP creates a nick, the 3′-OH end generated by the in-
cision is elongated by the replicative holoenzyme consti-
tuted by DNA polymerase (Pol)  or ε, PCNA and RF-C.
Through strand displacement synthesis, a 5′-rNMP termi-
nated flap is generated, which is cut by the nuclease Fen-1
and an intact DNA strand without rNMPs is reconstituted
by DNA ligase 1 (5). So far, the entire RER pathway was
reconstituted in vitro thanks to yeast enzymes and no other
Pol has been shown, up to now, to be able to act in RER
reactions (6).
In RNaseH2-deficient mammalian cells, there is the ac-
tivation of an alternative and highly mutagenic pathway
directed by Top-1 enzyme that is deleterious for genome
stability (7,8). Moreover, in humans the inactivation of
RNaseH2 causes the Aicardi-Goutier syndrome (AGS), a
rare genetic neurological disorder characterized by inflam-
matory response activation in the absence of exogenous
stimuli (4).
The DEAD-box RNA helicase DDX3X is a well-known
enzyme for its involvement and therapeutic relevance in vi-
ral infections and cancer (9). It operates in all the aspects of
RNA metabolism in addition to cell proliferation pathways
and innate immunity (9,10). DDX3X loss promotes tumori-
genesis (11), neurodegenerative diseases (12) and triggers
DNA damage and embryonic lethality in mice (13). More
important, recent evidence showed through chromatin im-
munoprecipitation analysis also a possible role of DDX3X
in genome stability maintenance: DDX3X binds promoter
regions regulating the expression of two DNA repair fac-
tors, DDB2 and XPA (10). Published data have implicated
DDX3X in the resolution of DNA:RNA hybrids and RNA
secondary structures, as well as in the degradation of RNAs
(14).
Different studies utilized specifically mutated poly-
merases to increase the level of misincorporated rNMPs in
the genome. Comparing cells with wild type- and deficient-
RNaseH2 enzyme, it appears clear that it is not just the ab-
sence of RNaseH2, but also of the ribonucleotide process-
ing that causes deleterious consequences. If the level of rN-
MPs exceeds a specific threshold, there is the insurgence of
cellular stresses also in the presence of a completely func-
tional RNaseH2 (4). Moreover, in prokaryotes the absence
of both RNaseH1 and 2 in mutant strains causes a level of
spontaneous mutagenesis that is lower than expected. This
means that there are probably some ‘backup enzymes’ into
the cell, less effective than RNaseH2, but still able to main-
tain partial genome integrity (6).
Thanks to biochemical in vitro characterization and pre-
liminary in vivo evidence, here we show that the RNA he-
licase DDX3X has RNaseH2-like activity able to initiate
RER in in vitro reconstituted systems and that its silencing
causes accumulation of rNMPs in cellular genome. More-
over, we demonstrate that the specialized DNA repair Pols
 and  can fully support in vitro reconstituted RER reac-
tions, with either RNaseH2 or DDX3X. These results sup-
port the existence of alternative RER pathways in human
cells, suggesting a hitherto unappreciated flexibility of cells
in responding to the threat posed by rNMPs incorporation.
MATERIALS AND METHODS
Chemicals
Unlabelled rNMPs and dNTPs were from Roche Molecu-
lar Biochemicals (Mannheim, Germany). All other reagents
were of analytical grade and were purchased from Merck
(Darmstadt, Germany) or Fluka (Munich, Germany).
Nucleic acids substrates
Oligonucleotides were purchased from Biomers.net GmbH
(Ulm, Germany) or Metabion AG (Steinkirchen, Ger-
many). The sequences of the substrates used are (bold letters
indicate ribonucleotides):





ds 24rC/24mer Substrate *D19R1D4: D24
5′-CTACGGCTCACACTATCTCACACT-3′
3′-GATGCCGAGTGTGATAGAGTGTGA-5′FAM
ds 24rC/24mer Substrate *D18R1D5: D24
5′-CTACGGCTCACACTATCTCACACT-3′
3′-GATGCCGAGTGTGATAGAGTGTGA-5′FAM


















Single- and double- underlined sequences indicate the hy-
bridization positions of the respective oligonucleotides, to
generate a dsDNA with a 24 nucleotides (nt) flap.
ds 55rC/55oxoG Substrate *D39R1D15: D398oxoG1D15





Each 6-carboxyfluorescein (FAM) 5′-labeled primer was
mixed to the complementary template oligonucleotide at 1:1
(M/M) ratio in the presence of 150 mM HEPES–KOH pH
7.4, 500 mM KCl, 10 mM MgCl2 and 250 mM NH4Ac,
heated at 95◦C for 5 min and then slowly cooled down at
room temperature.
Proteins production and purification
Human recombinant full length DDX3X was cloned in the
E. coli expression vector pET-30a(+). ShuffleT7 E. coli cells
were transformed with the plasmid and grown at 37◦C up to
OD600 = 0.7. DDX3X expression was induced with 0.5 mM
IPTG at 15◦C O/N. Cells were harvested by centrifugation,
lysed and the crude extract centrifuged at 100 000×g for
60 min at 4◦C in a Beckman centrifuge before being loaded
onto a FPLC Ni-NTA column from GE Healthcare (Up-
psala, Sweden). Column was equilibrated in Buffer A (50
mM Tris–HCl pH 8.0, 250 mM NaCl, 25 mM Imidazole
and 20% glycerol). After extensive washing in Buffer A, the
column was eluted with a linear gradient in Buffer A from
25 to 250 mM Imidazole. Proteins in the eluted fractions
were visualized on SDS-PAGE and tested for the presence
of DDX3X by Western Blot with anti-DDX3X A300-A474
from BETHYL (Montgomery, United States) at 1:4000 di-
lution in 5% milk. Fractions containing the purest DDX3X
protein were pooled and dialyzed using Slide-A-Lyzer®
MINI Dialysis Devices 20K MWCO from Thermo Scien-
tific (Rockford, United States) for 3 h (25 mM Tris–HCl
pH 8.0, 0.5 mM DTT, 100 mM NaCl, glycerol 20%) in or-
der to remove the salt excess. Finally, proteins were stored
at –80◦C.
Human recombinant DDX3X mutants here specified
were induced and purified as the full-length protein
(E256A/R262A, R351A, D347A/D350A). E256A and
R262A mutants were cloned in the Escherichia coli expres-
sion vector pET-30a(+) and BL21(DE3) cells were trans-
formed with the plasmids. Proteins induction and purifica-
tion were the same as for the full-length protein, with the
only difference that proteins were not dialyzed to avoid fur-
ther loss of material due to the dialysis procedure.
Human recombinant DDX3Xins (1–248/260–662) was
cloned in the E. coli expression vector pTrchisA. BL21 E.
coli cells were transformed with the plasmid and grown at
37◦C up to OD600 = 1. DDX3X expression was induced
with 0.5 mM IPTG at 15◦C O/N. Purification procedure
was the same of full-length protein.
Human recombinant DDX3X (132–607) truncated mu-
tant was expressed and purified as previously described (15).
Human recombinant Pols  and  (16), Pol  (17) and
RNaseH2 (18) were expressed and purified as described.
Human Fen-1 and Human DNA ligase 1 were both pur-
chased from Origene (Rockville, United States). Human re-
combinant full length DDX5 was cloned in the E. coli ex-
pression vector pET-30a(+). BL21(DE3) E. coli cells were
transformed with the plasmid and grown at 37◦C up to
OD600 = 0.7. DDX5 expression was induced with 0.5 mM
IPTG at 37◦C for 4 h. Cells were harvested by centrifugation
and lysed and the crude extract centrifuged at 13 000×g for
60 min at 4◦C in a Beckman centrifuge before being loaded
onto Dyanabeads® His-Tag Isolation & Pulldown beads
from Life Technologies (Rockford, United States). Protein
was eluted according to the manual.
Proteomic analysis
2-D electrophoresis (2-DE) and mass spectrometry. The
first electrophoresis run (IsoElectroFocusing, IEF) was
performed on 18 cm long, non-linear pH 3–10 gradient
Immobiline-polyacrylamide DryStrip gels (IPG strips; GE
Healthcare) using the Ettan™ IPGphor system (GE Health-
care). For analytical and MS-preparative gels, strips were
rehydrated with 20 and 60 g of protein, respectively, dena-
tured in 350 l of 2-DE buffer [8M urea, 4% (w/v) CHAPS,
and 1% (w/v) dithioerythritol (DTE)] and 0.2% or 2% (v/v)
IPG-buffer (pH 3–10; GE Healthcare), for 1 h at 0 V and
overnight at 30 V, at 16◦C. IEF was performed at 16◦C and
complete protein focusing was reached when a total of 100
000 Vh was applied. The focused strips were equilibrated for
12 min in 6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS, 0.05
M Tris–HCl pH 6.8, 2% (w/v) DTE; and for further 5 min in
6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS, 0.05 M Tris–
HCl pH 6.8, 2.5% (w/v) iodoacetamide, and trace of bro-
mophenol blue. The second dimension (SDS-PAGE) was
run on house-made 9–16% polyacrylamide linear gradient
gels. at 10◦C, in Protean II Multi Cell (Bio-Rad Laborato-
ries, Hercules, CA, USA) applying 40 mA/gel constant cur-
rent. The run was stopped when the bromophenol blue dye
reached the end of the gel. Analytical and MS-preparative
gels were stained with ammoniacal silver nitrate and with
a MS-compatible silver staining, respectively. 2-DE stained
gels were scanned using the ImageScanner III (GE Health-
care), and the acquired images were analyzed by ImageMas-
ter 2D Platinum v6.0 software (GE Healthcare).
Protein spots cut from MS-preparative gels, were
destained and acetonitrile dehydrated. Spots were re-
hydrated in trypsin solution (Sigma, St. Louis, United
States) and in-gel trypsin digested overnight at 37◦C. 1.25
l of each tryptic peptides sample was directly spot-
ted onto the MALDI target and air-dried. Then 0.75 l
of matrix solution (a saturated solution of alpha-cyano-
4-hydroxycynnamic acid in 50% (v/v) acetonitrile and
0.5% (v/v) trifluoroacetic acid) was added to the dried
samples and allowed to dry again. Protein identification
was carried out by peptide mass fingerprinting (PMF) us-
ing an Ultraflex III MALDI-TOF/TOF mass spectrometer
(Bruker Daltonics, Billerica, USA). Mass spectra were ac-
quired with the mass spectrometer in reflector positive mode
with a laser frequency of 100 Hz and analyzed by Flex Anal-
ysis software v.3.0. PMF database searching was carried out
in SwissProt database (version 2018 01; 556568 sequences;
199530821 residues) using the on-line available Mascot
software (Matrix Science Ltd., London, UK, http://www.
matrixscience.com). The following database search criteria
were set: E. coli or Homo sapiens as taxonomy, 100 ppm
as peptide tolerance, trypsin as the digestion enzyme with
one allowed missed cleavage, cysteine carbamidomethyla-
11554 Nucleic Acids Research, 2020, Vol. 48, No. 20
tion as fixed modification, and methionine oxidation as
variable modification. For protein identifications the num-
ber of matched peptides, the extent of sequence coverage,
and the probabilistic score were considered.
Liquid chromatography–tandem MS (LC–MS/MS) anal-
ysis and protein identification. Entire gel lanes were pro-
cessed with STAGE-diging protocol as described (19) and
peptides were resuspended in 10 l of solvent A. 3 l
were injected on a quadrupole Orbitrap Q-Exactive mass
spectrometer (Thermo Scientific) coupled with an UH-
PLC Easy-nLC 1000 (Thermo Scientific) with a 25 cm
fused-silica emitter of 75 m inner diameter. Columns
were packed in-house with ReproSil-Pur C18-AQ beads (Dr
Maisch Gmbh, Ammerbuch, Germany), 1.9 m of diame-
ter, using a high-pressure bomb loader (Proxeon, Odense,
Denmark).
Peptides separation was achieved with a linear gradient
from 95% solvent A (2% ACN, 0.1% formic acid) to 40%
solvent B (80% acetonitrile, 0.1% formic acid) over 30 min
and from 40% to 100% solvent B in 2 min at a constant flow
rate of 0.25 L/min, with a single run time of 33 min in case
of single bands, or with a linear gradient from 95% solvent
A to 40% solvent B over 55 min and from 40% to 100%
solvent B in 5 min at a constant flow rate of 0.25 l/min for
peptides obtained with STAGE-diging.
MS data were acquired using a data-dependent top 12
method, the survey full scan MS spectra (300–1750 Th) were
acquired in the Orbitrap with 70 000 resolution, AGC tar-
get 1e6, IT 120 ms. For HCD spectra resolution was set to
35000, AGC target 1e5, IT 120 ms; normalized collision en-
ergy 25% and isolation width of 3.0 m/z.
For protein identification the raw data were processed us-
ing Proteome Discoverer (version 1.4.0.288, Thermo Fis-
cher Scientific). MS (2) spectra were searched with Mas-
cot engine against Uniprot CP HomoSapiens 20170110
database (unknown version, 156576 entries) and the
Uniprot Swissprot all 20170110 database (selected for E.
coli, unknown version, 23014 entries), with the following
parameters: enzyme Trypsin, maximum missed cleavage
2, fixed modification carbamidomethylation (C), variable
modification oxidation (M) and protein N-terminal acetyla-
tion, peptide tolerance 10 ppm, MS/MS tolerance 20 mmu.
Peptide Spectral Matches (PSM) were filtered using perco-
lator based on q-values at a 0.01 FDR (high confidence).
Proteins were considered identified with 2 unique high con-
fident peptides (20). Scaffold (version Scaffold 4.3.4, Pro-
teome Software Inc., Portland, OR) was used to validate
MS/MS based peptide and protein identifications. Peptide
identifications were accepted if they could be established
at >95.0% probability by the Peptide Prophet algorithm
(21) with Scaffold delta-mass correction. Protein identifica-
tions were accepted if they could be established at >99.0%
probability and contained at least 3 identified peptides. Pro-
tein probabilities were assigned by the Protein Prophet al-
gorithm (22). Proteins that contained similar peptides and
could not be differentiated based on MS/MS analysis alone
were grouped to satisfy the principles of parsimony. Proteins
sharing significant peptide evidence were grouped into clus-
ters.
Nuclease assays
The nuclease activity of both human RNaseH2 and
DDX3X enzymes was monitored on a double stranded (ds)
DNA bearing a single ribonucleotide in the strand labelled
at the 5′-end with a 6-FAM fluorescent group. A final con-
centration of 50 nM DNA substrate was used in the exper-
iments. The amounts of RNaseH2 and DDX3X proteins
are indicated in the respective figure legends. Reactions were
performed in 20 mM Tris–HCl pH 8.8, 10 mM (NH4)2SO4,
10 mM KCl, 2 mM MgSO4, 0.1% TritonX-100 at 37◦C for
60 min (unless specified in figure legends). Finally, the reac-
tion mixtures were stopped by addition of standard dena-
turing gel loading buffer (95% formamide, 10 mM EDTA,
xylene cyanol and bromophenol blue), heated at 95◦C for 5
min and loaded on 7 M urea 12% polyacrylamide (PAA) gel,
run at 40 W for 2 h in TBE buffer. Substrates and products
were quantified by laser scanning densitometry (Typhoon-
TRIO, GE Healthcare).
Non denaturing gel-based helicase assays
The helicase activity of DDX3X was monitored by mea-
suring the conversion of a double stranded (ds) RNA (la-
beled at the 5′-end of one strand with a 6-FAM fluorescent
group) into single stranded (ss) nucleic acid. A final con-
centration of 50 nM RNA substrate was used in the exper-
iments, unless otherwise stated. The amounts of DDX3X
proteins are indicated in the respective figure legends. Re-
actions were performed in 20 mM Tris–HCl pH 8, 2 mM
DTT, 70 mM KCl and 1 mM ATP, 2 mM MgCl2 at 37◦C
for 30 min (unless otherwise stated in figure legends) and
stopped by adding EDTA 50 mM pH 8. Products were sep-
arated through non-denaturing 7% PAGE at 5 W for 3 h in
TBE buffer at 4◦C.
Substrates and products were quantified by laser scan-
ning densitometry (Typhoon-TRIO, GE Healthcare).
Helicase assay based on fluorescence resonance energy trans-
fer (FRET)
The FRET helicase assay was performed as described (23).
Briefly, the dsRNA substrate for the helicase assay was pre-





• DNA capture 5′-TAGTACCGCCACCCTCAGAACC-3′
The sequence in Fluo-FAM complementary to Qu-
BHQ1 is underlined. Flu-FAM carries a 6- carboxyfluo-
rescein fluorophore at its 3′ end, while Qu-BHQ1 carries a
Black Hole quencher group at its 5′ end. The DNA cap-
ture oligonucleotide is complementary to the Qu-BHQ1
oligonucleotide but bears no modifications.
Helicase assay using the dsRNA substrate was performed
in 20 mM Tris-HCl pH 8, 70 mM KCl, 2 mM MgCl2, 2 mM
dithiothreititol, 12 units RNasin (Promega, MD, USA), 2
mM ATP, 100 nM capture strand and different and increas-
ing concentration of dsRNA in 20 l of reaction volume.
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The unwinding reaction was started by adding DDX3X re-
combinant protein and R351A mutant and carried out at
37◦C for 40 min using a LightCycler 480 (Roche). The flu-
orescence intensity was recorded every 30 s. Data of fluo-
rescence signals were analyzed by linear interpolation and
the corresponding slope values were used to determine the
apparent unwinding rate.
Ribonucleotide excision repair assays
The ribonucleotide excision repair (RER) assay was recon-
stituted in vitro by reproducing all steps of physiological
RER: incision of a single rMNP embedded in a dsDNA by
RNaseH2 or DDX3X, was followed by DNA synthesis with
Pols ,  or , 5′ rMNP-terminated flap removal by Fen-1
and ligation by DNA ligase 1 to generate as final product
a dsDNA without embedded rMNP. A final concentration
of 50 nM DNA substrate was used in the experiments. The
amounts of RNaseH2, DDX3X, Pols  and , PCNA and
dNTPs are indicated in the respective figure legends. Reac-
tions were performed in 20 mM Tris–HCl pH 8.8, 10 mM
(NH4)2SO4, 10 mM KCl, 2 mM MgSO4, 0.1% Triton X-
100 at 37◦C for 60 min (unless specified in the figures). To
prove that no more ribonucleotides were present into the
fully repaired DNA substrate, at the end of the RER reac-
tion we inactivated all the enzymes at 75◦C for 10 min. Then,
we left the reaction at room temperature for 10 min and we
proceeded adding 100 nM of human RNaseH2 for 45 min.
The dsDNA product without embedded rMNP, will be re-
sistant to the digestion of RNaseH2 enzyme. Finally, the re-
action mixtures was stopped by addition of standard dena-
turing gel loading buffer (95% formamide, 10 mM EDTA,
xylene cyanol and bromophenol blue), heated at 95◦C for
5 min and loaded on 7 M urea 12% polyacrylamide (PAA)
gel at 40 W for 2 h in TBE buffer. Substrates and products
were quantified by laser scanning densitometry (Typhoon-
TRIO, GE Healthcare).
Cell extracts and DDX3X quantification
As already described (23) 107 cells were ruptured with a
Dounce homogenizer in Lysis Buffer (50 mM Tris–HCl pH
8.0, 0.1% SDS, 350 mM NaCl, 0.25% Triton X-100, pro-
tease inhibitor cocktail (Sigma). The lysate was incubated
30 min on ice, sonicated for 5 min (at 30 s intervals) and
centrifuged at 15 000 × g for 10 min at 4◦C. The protein con-
centration in the supernatant (crude extract) was quantified
with Bradford. For DDX3X quantification, increasing con-
centrations of crude extract (5, 10, 20, 40 g) were loaded
on a SDS-PAGE alongside known concentrations (50 ng,
100 ng, 150 ng, 200 ng) of recombinant purified DDX3X.
Separated proteins were subjected to Western Blot analy-
sis with anti-DDX3X A300-475A (BETHYL) at 1:4000 di-
lution in 5% milk. The blot was next incubated with an
HRP-conjugated secondary antibody diluted to 1:5000 and
the bands corresponding to DDX3X were visualized with
Enhanced Chemiluminescent Substrate (Westar Nova 2.0,
Cyanagen, Bologna, Italy) using a ChemiDoc™ XRS (Bio-
Rad) apparatus. The intensity of the bands was measured
by densitometry and the values obtained for the purified
DDX3X were plotted as a function of the protein concen-
tration and analysed by linear interpolation to derive a ref-
erence curve, whose slope corresponded to the estimated
intensity (I) × ng−1 (DDX3X) value. This parameter was
used to calculate the I × ng−1 values for the DDX3X in
the cell extract, from the intensities of the DDX3X bands
in the corresponding cell extract (CE) samples. The mean I
× ng−1 (CE) value was used to calculate the ng of DDX3X
× l−1 of extract, and then the total ng of DDX3X present
in the extract. This value was divided for the total num-
ber of cells used (107), to derive the ng DDX3X/cell. Based
on the known molecular weight of DDX3X, the Avogadro
number and assuming a mean cellular volume of 6.55 ×
10−11 l, the final molar concentration of DDX3X per cell
was calculated. Each experiment was repeated three times,
with each blot carrying a reference curve alongside the ex-
tract samples, to account for variations in loading/transfer
efficiency. The reference I × ng−1 (DDX3X) value obtained
was anyway comparable across the different experiments
(±20% variation).
Kinetic analysis
Time-dependent product accumulation was fitted to the
simple exponential equation:
A(1 − e−kapp t) (1)
where A is the burst constant, kapp is the apparent reaction
rate and t is time.
Dependence of the reaction products from DDX3X con-





where Eobs is the observed enzymatic activity in the presence
of each enzyme dose E0; Emax is the maximal enzymatic ac-
tivity; nH is an exponential term to take into account sig-
moidal dose–response curves.
Dose-dependent inhibition of the DDX3X nuclease reac-
tion by ATP was fitted to the equation:
Eobs = Emax/ (1 + ([ATP] /ID50)nH ) (3)
where Eobs is the observed enzymatic activity in the pres-
ence of each ATP dose ([ATP]); Emax is the maximal enzy-
matic activity in the absence of ATP; ID50 is the ATP con-
centration inhibiting the enzymatic reaction by 50%; nH is
an exponential term to take into account sigmoidal dose–
response curves.
To calculate Vmax and Km constants, data (in triplicate)
were plotted and analyzed by least-squares nonlinear re-
gression and fitted to the following equation:
v = Vmax/ (1 + (Km/[S]n)) (4)
where v is the apparent reaction velocity at each substrate
concentration, Vmax is the maximum rate of the reaction,
Km is the Michaelis–Menten constant, S is the variable sub-
strate concentration, n is an exponential term to take into
account sigmoidal dose–response curves, due to the positive
cooperativity of DDX3X binding to RNA (24).
The turnover constant kcat was calculated as
Vmax/(enzyme concentration) and the RNA substrate
binding efficiency of our enzymes was calculated as the
kcat/Km ratio.
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Data were fitted to Equations (1), (2), (3) and (4) with the
program GraphPad Prism 6.0.
Transfection of HEK293T cells for engineered lentivirus
preparation
For lentivirus preparation, 3–3.5 × 106 HEK293T cells
were seeded in 10 cm tissue culture dishes in 10 ml Dul-
becco’s modified Eagle’s medium (Sigma) containing 10%
fetal bovine serum (Sigma) and 20 g/ml gentamycin
(Sigma) and grown for 24 h in a humidified 5% CO2 atmo-
sphere. After 2 h before transfection, cell medium was re-
placed. Then, cells were transfected with 13.2 g Inducible
Dharmacon™ TRIPZ™ Lentiviral shRNA (GE Healthcare
Lafayette, United States), 10 g pSPAX2 vector (Dharma-
con™, GE Healthcare) and 4 g pMD2 vector (Dharma-
con™, GE Healthcare) diluted in 50 mM Hepes pH 7.12, 140
mM NaCl, 750 nM Na2HPO4 and 125 mM CaCl2. To en-
hance transfection efficiency, 100 M Chloroquine (Sigma)
was added to the cells. Cell medium was changed 14–16 h
after transfection and viruses were collected for the two fol-
lowing days.
All this work was done in Biosafety Level 2 (BSL2) labo-
ratory.
Cells transduction and DDX3X-knockdown induction
One day prior to transduction, 500 000–600 000 U2OS cells
were seeded in 2 ml Dulbecco’s modified Eagle’s medium
(Sigma) containing 10% fetal bovine serum (Sigma) and
20 g/ml gentamycin (Sigma) in 6 well plates and grown
in a humidified 5% CO2 atmosphere. Then, cell medium
was replaced with 2 ml of viral particles and 4 g/ml pro-
tamine sulfate (Sigma) to enhance the transduction effi-
ciency. After 3–4 h, new fresh medium containing viral par-
ticles was added for each plate and left O/N. Finally, cells
were washed with Phosphate Saline Buffer (Sigma) and
new fresh medium Dulbecco’s Modified Eagle’s medium
(Sigma) containing 10% fetal bovine serum (Sigma) and
20 g/ml gentamycin (Sigma) was added. Cells grown for
24 h in a humidified 5% CO2 atmosphere without any ad-
ditional selection. Then, since cells that have integrated
the Inducible Dharmacon™ TRIPZ™ Lentiviral shRNA
(pTRIPZ shDDX3 130, V2THS 228965, GE Healthcare)
possess Puromycin resistance, a dose-escalation curve of
Puromycin (Sigma) was used to select resistant cells. All
this work was done in Biosafety Level 2 (BSL2) laboratory.
Knockdown (KD) of DDX3X in U2OS cells (shDDX3X
cells) or in the non-silencing vector shRNA (NSC) con-
trol cells were both induced adding 1 g/ml Doxycycline
(Sigma) into the cell medium and simultaneously maintain-
ing cells in Puromycin selection (2 g/ml). Doxycycline was
maintained for 48–72 h and then cells were harvested and
KD efficiency was checked by western blot.
siRNA-mediated protein depletion
All siRNAs were purchased from Dharmacon™-Horizon
Discovery and were transfected using RNAiMAX (In-
vitrogen, Carlsbad, USA) according to manufacturer in-
structions. siRNAs were used at final concentration of 5
nM and 25 nM for DDX3X and RNaseH2 silencing, re-
spectively. U20S cells grow in Dulbecco’s modified Eagle’s
medium (Euroclone, Milan, Italy) containing 10% fetal
bovine serum (Immunological Sciences, Rome, Italy) and 20
g/ml gentamycin (Euroclone). Medium was changed 24 h
after transfection and samples collected after 72 h. The fol-
lowing mRNA target sequences were used:
RNASEH2A siRNAs pool: Target sequences 5→3′
CGGGAAAGGCUGUUUGCGA; AAAUGGAGGACACGGACUU;
AUGCAUUGGACCAGGGCGU; AGACCCUAUUGGAGAGCGA
DDX3X siRNAs pool: Target sequences 5′→3′
GCAAAUACUUGGUGUUAGA; ACAUUGAGCUUACUCGUUA;
CUAUAUUCCUCCUCAUUUA; GGUAUUAGCACCAACGAGA
Non-Targeting siRNAs pool: Target sequences 5′→3′
UAGCGACUAAACACAUCAA; UAAGGCUAUGAAGAGAUAC;
AUGUAUUGGCCUGUAUUAG; AUGAACGUGAAUUGCUCAA
Cell extracts and western blot
U20S cell pellets were lysed for 30 min on ice in 50 mM pH
8 Tris–HCl, 0.1% SDS, 350 mM NaCl, 0.25% Triton X-100
in the presence of Protease Inhibitor Cocktail 1X (Sigma).
Then, samples were sonicated (at 30 s intervals) and cen-
trifuged at 4◦C for 10 min at 15 000 × g. The soluble portion
of the extract was then quantified by Bradford assay (Bio-
Rad) and loaded on SDS-Page gels. After gels running, pro-
teins were transferred to a nitrocellulose membrane with a
pore size of 0.45 m (Ge Healthcare) using Trans-Blot®
Turbo TM device (Bio-Rad). Finally, the following pri-
mary antibodies were used: rabbit polyclonal anti-DDX3X
A300-475A antibody (1:2000 dilution) (BETHYL), mouse
201055 anti-actin (1:1000 dilution) (Santa Cruz Biotech-
nology, Dallas, United States), mouse MAB3574 vinculin
(1:10 000 dilution) (Millipore, Temecula, USA) and rabbit
ab83943 anti-RNaseH2A (1:500 dilution) (Abcam, Cam-
bridge, England).
Riboassay
The protocol is based on the one previously published (25)
with further modifications and optimization (Maffia and
Sabbioneda, manuscript in preparation). Specifically, ge-
nomic DNA was extracted using NucleoSpin® Tissue kit
(Macherey-Nagel, Düren, Germany). Then, 1 g of ge-
nomic DNA was digested with 1 U of E. coli RNaseH2
(BioLabs, Euroclone) or with 50 nM human recombinant
RNaseH2 and the reaction was led in a dry heating block
(Eppendorf® Thermomixer®) at 37◦C with constant shak-
ing at 550 rpm for 2.5 h. Reaction was stopped on ice for 30
min and nick translation reaction started trough the addi-
tion of 1 U of E. coli DNA pol I (Biolabs, Euroclone) and 2
l of Atto647N-dUTP pH 7.5 NT Labelling Kit (Jena Bio-
sciences, Löbstedter, Germany) at 16◦C for 1 h.
Finally, the reaction was stopped by addition of standard
gel loading buffer and loaded on a 1% agarose gel at 100 V
for 2 h in TBE buffer. Ethidium bromide and Atto647N-
dUTP signals were detected by laser scanning densitome-
try (Typhoon-TRIO, GE Healthcare) and quantified with
ImageQuant TL (Typhoon-TRIO, GE Healthcare) normal-
izing Atto647N-dUTP signals with the Ethidium bromide
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ones. Quantitation of undigested genomic DNAs were sub-
tracted from quantitation of digested genomic DNAs and
P values were calculated using the Student’s t-test.
RESULTS
Human DDX3X has RNaseH2-like activity
It is already known that DDX3X is able to resolve
DNA:RNA hybrids and RNA secondary structures and it
has been implicated in RNA degradation processes (14).
We have been studying DDX3X protein since more than
ten years, as a promising druggable antiviral and anticancer
target (9). During the course of our biochemical studies,
we constantly detected in our purified preparations of full
length DDX3X an unexpected exoribonuclease activity of
this enzyme. Being aware of preliminary implications of
DDX3X in genome stability (10) and of the existence of
double-functioning enzymes with helicase/RNase activities
(26,27) we tested a possible DDX3X RNaseH2-like activity.
When incubated in the presence of a specific oligonucleotide
dsDNA substrate containing a single rCMP embedded in
one strand at a specific position (Substrate *D39R1D15: D55
Figure 1A), recombinant purified human DDX3X (Supple-
mentary Figure S1a and b) cut at the 5′ side of the sin-
gle rNMP, generating a product identical to the one of
RNaseH2 (Figure 1A, compare lanes 1–5 with lanes 6–
10), albeit with lower efficiency (Figure 1B). Apparent rates
of digestion were 0.016 min−1 M−1 for DDX3X and 3.3
min−1 M−1 for RNaseH2, respectively. To the best of our
knowledge, no other human enzyme besides RNaseH2 has
been described so far to catalyze single rNMP excision from
dsDNA.
DDX3X cutting was restricted to the rNMP position
and independent from the surrounding sequence, as hav-
ing the rCMP at two different positions one nucleotide up-
stream on a different DNA substrate (Figure 1C, Substrates
*D19R1D4: D24 and *D18R1D5: D24), also generated the ex-
pected products (Figure 1C, lanes 2 and 5), These products
are again identical to those generated by RNaseH2 (Figure
1C, lanes 3 and 6), confirming that rCMP acted as specific
recognition site for DDX3X.
On a dsDNA oligonucleotide with an embedded stretch
of 4 rNMPs (Substrate *D19R4D18: D41), RNaseH2 pref-
erentially cut 5′ of the last rNMP (28) downstream the
RNA–DNA junction, generating a 22 nt product (Figure
1D, lanes 4–6). Differently, DDX3X generated 19–22 nt
products (Figure 1D, lanes 7–9), with similar incision rates
for each position (Supplementary Figure S1c), thus show-
ing no preference between a DNA/RNA or an RNA/RNA
phosphodiester bond.
On a dsDNA oligonucleotide with an embedded ribonu-
cleotide opposite to an 8xoG base (Substrate *D39R1D15:
D398oxoG1D15), DDX3X cuts at the rNMP position with
the same efficiency as the control substrate (Figure 1E, lanes
2–5 and Supplementary Figure S1d). This is in contrast with
the reported reduced activity of RNaseH2 in removing rN-
MPs opposite such lesion (29).
Mass spectrometry analysis using different approaches
by two independent laboratories of two different prepara-
tions of recombinant DDX3X purified from E. coli, showed
that none of the few co-purifying E. coli contaminants pos-
sessed RNase or any other kind of nuclease activity (Supple-
mentary Tables S1 and S2). The major contaminant was fer-
ric uptake regulation protein, which binds metal ions such
as the Ni2+ present on the medium used for affinity purifi-
cation. Thus, the observed RNaseH2-like activity could be
firmly attributed to DDX3X. Comparison with the related
human RNA helicase DDX5 (43% identity, 60% similarity)
failed to detect RNaseH2-like activity, suggesting that it was
peculiar to DDX3X (Supplementary Figure S1e–g).
RNaseH2-like and helicase activities of DDX3X are differen-
tially regulated by ATP binding and protein oligomerization
In helicase assays, our DDX3X preparation preferentially
unwound a dsRNA substrate with a ss-3′ overhang (Sub-
strate *R18: R38, Figure 2A), in agreement with published
results (24). As shown in Figure 2B, no unwinding was ob-
served on the dsDNA/rNMP hybrid (Substrate *D18R1D5:
D24) even at high DDX3X concentrations in the presence of
ATP (Figure 2B, lanes 2–5). Without ATP (Figure 2B, lanes
8–11), at the DDX3X concentrations which cut Substrate
*D18R1D5: D24 in nuclease assays, digestion products ap-
peared (Figure 2B, lanes 10–11 marked by asterisks). Since
the gel was run under non-denaturing conditions, cutting
of the labelled strand at the rCMP position possibly caused
dissociation of the nicked DNA strand during the gel run.
Thus, the RNaseH2-like activity of DDX3X did not require
its RNA helicase activity nor ATP.
In helicase assays DDX3X showed a sigmoidal depen-
dence of unwinding with respect to the enzyme concentra-
tion (K1/2 = 0.26 M, cooperativity index nH = 1.5) (Fig-
ure 2C), suggesting protein oligomerization, according to
published results (24). In the nuclease reaction no coop-
erativity was observed (K1/2 = 0.32 M, nH = 0.7) (Fig-
ure 2D). The nuclease activity of DDX3X was inhibited
by increasing amounts of ATP (Figure 2E), with a sig-
moidal dose-dependence from the ATP concentration (ID50
= 5.9 mM, nH = 2.7), suggesting that binding of ATP trig-
gered DDX3X oligomer formation, as suggested for other
DEAD-box helicases (30). Thus, DDX3X apparently inter-
acted with the nucleic acid substrate with a different stoi-
chiometry when acting as a nuclease rather than a helicase
and its oligomeric state was regulated by ATP (31,32).
Sequence and structural comparison reveal conserved amino
acids in the catalytic site of RNaseH2 and DDX3X
Attempting to rationalize the observed nuclease activity,
previously unnoticed in human DDX3X or its orthologs
in other organisms, a structural modeling comparison was
made between catalytically important regions of RNaseH2
and DDX3X. Because of the lack of complete crystal struc-
tures of human RNaseH2, we selected the structure of the
murine enzyme (amino acid identity 86.62%). The DDX3X
crystal structure in its open conformation was used (33)
since our results indicated that DDX3X acts as a monomer
(i.e. in open conformation) in its RNaseH2-like activity.
Sequence (Figure 3A) and structural (Figure 3B) align-
ments revealed that Arg38 of the RNaseH2 catalytic motif
-DEAGR- (28) could be aligned to Arg351 of the DDX3X
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Figure 1. Human DDX3X has RNaseH2-like activity. (A) Time course of DDX3X (lanes 1–5) and RNaseH2 (lanes 6–10) digestions of Substrate
*D39R1D15: D55. (B) Apparent digestion rates for DDX3X and RNaseH2 enzymes on Substrate *D39R1D15: D55. Values are the means of three inde-
pendent estimates ± S.D. (C) Digestion by DDX3X (lanes 2 and 5) and RNaseH2 (lanes 3 and 6) on Substrate *D19R1D4: D24 and Substrate *D18R1D5:
D24 respectively. Lanes 1 and 4: Substrates *D19R1D4: D24 and *D18R1D5: D24 alone, respectively. (D) Substrate *D19R4D18: D41 in the presence of
RNaseH2 (lanes 4–6) or DDX3X (lanes 7–9). Lanes 1–2 control reactions with RNaseH2 and Substrate *D19R1D4: D24. Lane 3 Substrate *D19R4D18:
D41 alone. Lanes 10, 11 oligonucleotide size markers of defined lengths, used to better identify the different digestion products. (E) Time course of DDX3X
digestion of Substrate *D39R1D15: D55 (lanes 1–5) and Substrate *D39R1D15: D398oxoG1D15 (lanes 7–11). Control reactions with RNaseH2 of Substrate
*D39R1D15: D55 (lane 6) and Substrate *D39R1D15: D398oxoG1D15 (lane 12) respectively.
catalytic motif -DEADR- (34) both residues taking simi-
lar interactions with the RNA substrate in both enzymes
(Figure 3B). Such interactions were lost in the recently pub-
lished structure of DDX3X in a closed dimeric conforma-
tion bound to dsRNA (31) supporting our hypothesis of a
monomeric conformation of DDX3X when displaying its
RNaseH2-like activity.
The RNaseH2-like activity of DDX3X requires its RNA and
ATP binding domains
To verify our modeling, we mutated Arg351 into Ala. The
purified R351A DDX3X mutant (Supplementary Figure
S2a), displayed a kcat/Km reduction of 5.5-fold in helicase
activity if compared to wild type (Supplementary Figure
S2b). More interestingly, R351A displayed also >90% re-
duced nuclease activity with respect to the wild type (Figure
3D, E), similarly to the reported strongly reduced nuclease
activity of RNaseH2 mutant R38A (35). To further identify
other domains/residues responsible for the nuclease activ-
ity of DDX3X, we used a series of DDX3X mutants (Figure
3C and Supplementary Figure S2a) available in our labora-
tory.
The DDX3X double mutant D347A/D350A (DADA)
lacking ATPase/helicase activity (36) also displayed re-
duced nuclease activity (Figure 3D and E). A deletion mu-
tant (1–248/260–662) lacking the DDX3X-specific 10 aa in-
sertion (aa 249–259) named ‘unique motif ’, important for
RNA recognition, was shown to have reduced nucleic acid
binding and helicase activity (36). It showed almost unde-
tectable nuclease activity with respect to wild type (Figure
3D and E). Ongoing molecular modeling and biochemical
studies in our laboratory identified Glu256 inside this mo-
tif and Arg262 four residues immediately downstream, as
important for RNA interaction and unwinding (37). The
mutants E256A and R262A also showed strongly reduced
RNaseH2-like activity (Figure 3D and E) and the dou-
ble mutation E256A/R262A almost completely abolished
DDX3X nuclease activity (Figure 3D and E). Next, we ob-
served that the minimal catalytic core of DDX3X (aa 132–
607) showed no detectable nuclease activity (Figure 3D and
E), despite conserved helicase and ATPase activities (15).
Interestingly, the closely related enzyme DDX5 also did not
show nuclease activity despite the presence of conserved
ATPase and RNA binding domains. DDX5 bears differ-
ent N- and C-terminal domains with respect to DDX3X
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Figure 2. DDX3X RNaseH2-like activity is not dependent by its helicase activity and is inhibited by ATP. (A) Titration of DDX3X wild type (lanes 2–6)
in helicase reaction with a dsRNA substrate 18/38mer with a 20 nt 3’-ss overhang (Substrate *R18: R38). Lane 1: Substrate *R18: R38 alone. Lane 7: 18mer
single strand. (B) Native PAGE of the products of DDX3X helicase reaction with Substrate *D18R1D5: D24 in the presence (lanes 1–5) or in the absence
(lanes 7–11) of ATP. Lanes 6, 12: ss24mer as marker. (C) Dependence of the DDX3X helicase activity from the enzyme concentration. (D). Dependence
of the DDX3X nuclease activity from the enzyme concentration. (E) Inhibition of DDX3X nuclease activity by ATP. All values are the means of three
independent estimates ± S.D.
and it lacks the DDX3X unique motif. Thus, the observed
RNaseH2-like activity of DDX3X requires its ATPase and
RNA binding domains, including the unique motif in ad-
dition to the N- and C-terminal domains which are not
present in the minimal catalytic core (aa 132–607).
In vitro reconstitution of ribonucleotide excision repair with
specialized DNA polymerases  and 
It is still unclear whether other Pols, besides Pols /ε, might
perform the synthesis step of RER pathway in eukaryotes.
In order to reconstitute the full RER reaction in vitro, we in-
cubated human RNaseH2, human Fen-1 and human DNA
ligase 1 not only with the canonical human Pol , but also
in combination with the X-family DNA repair enzymes hu-
man Pols  and  on a dsDNA substrate bearing a single
rCMP at position +39 (Substrate *D39R1D15: D55) and a
dsDNA oligonucleotide with an embedded stretch of four
rNMPs (Substrate *D19R4D18: D41) both long enough to al-
low productive binding by Fen-1. Starting from Substrate
*D39R1D15: D55, RNaseH2 generated the expected 39 nt
product (Figure 4A, lane 2), allowing subsequent incorpo-
ration by Pol  in the presence of dNTPs at their intracel-
lular physiological range (50 M) (Figure 4A, lane 3). Ad-
dition of Fen-1 and DNA ligase 1 allowed flap removal and
ligation, generating a fully ligated 55 nt repair product (Fig-
ure 4A, compare lane 3 with lane 4). The flap cutting activity
of our Fen-1 was independently checked and confirmed on a
canonical flap substrate (Supplementary Figure S2c). This
product was resistant to degradation by RNaseH2 added
back after the ligation step, indicating that it did not con-
tain rCMP (Figure 4A, lane 5). In an equivalent experiment
with Pol  and PCNA (using 100 M dNTPs), strand dis-
placement synthesis (Figure 4A, lane 6) was followed by for-
mation of RNaseH2-resistant ligated 55 nt product only in
the presence of both Fen-1 and DNA ligase 1 (Figure 4A,
compare lane 7 with 8). In the presence of a stretch of 4 rN-
MPs (Substrate *D19R4D18: D41) and RNaseH2, reactions
with Pol  and  in the conditions previously described, gen-
erated a fully ligated 41 nt repair product only in presence of
Fen1 and DNA ligase 1 (Figure 4B, compare lane 3 with 4
for Pol  activity and lane 6 with 7 for Pol ). These products
were resistant to degradation by RNaseH2 added back after
the ligation steps, indicating that they did not contain rN-
MPs and that fully repair products could be obtained also
starting from a stretch of four rNMPs with both canonical
and non-canonical polymerases (Figure 4B, lane 5 for Pol 
and lane 8 for Pol ).
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Figure 3. Identification of DDX3X residues important for its RNaseH2-like activity. (A) Sequence alignment showing amino acid (aa) similarities between
the conserved -DEAD- (box II) helicase motif of DDX3X and the catalytic site of human RNaseH2. Red letters indicate catalytically important residues.
Green shading indicated identical and cyan shading similar aa. The numbers of the aa residues corresponding to each selected region are boxed. (B)
Structure comparison between human DDX3X in open conformation (PDB ID: 5e7I) on the left and mouse RNaseH2 (PDB ID: 3KIO) of the region
surrounding Arg351 of DDX3X (left) and Arg38 of RNaseH2 (right), showing the hydrogen bond formed by these residues with the RNA substrate.
Arg351 in DDX3X and Arg38 in RNase H2 were similarly positioned within these regions. (C) Graphical representation of all the DDX3X mutants and
DDX5 protein. N and C indicate the N-terminal and C-terminal of the proteins respectively. Boxes represent all the conserved motifs of DEAD-box
proteins (with the addition of DDX3 unique motif). Red letters indicate single aa mutations. (D) Nuclease activities of the DDX3X mutants and DDX5
protein relative to DDX3X wild type (taken as 100%). All catalytic activities were assessed on Substrate *D39R1D15: D55. Values are the mean of four
independent experiments ± S.D. All proteins were tested at 2 M. (E) Summary table of the catalytic activities shown in panel D.
We observed that also the DNA repair Pol  could
operate in RER. Performing assays with both Substrates
*D39R1D15: D55 and *D19R4D18: D41, in the presence of
dNTPs at their intracellular physiological range (50 M),
RNaseH2 generated the expected products (Figure 4C, lane
2 and Figure 4D, lane 2 respectively), addition of Pol  re-
sulted in nucleotide incorporation (Figure 4C, lane 4 and
Figure 4D, lane 4 respectively) and adding both Fen-1 and
DNA ligase 1, fully ligated repair products appeared (Fig-
ure 4C, compare lane 2 with lane 4 for Substrate *D39R1D15:
D55; Figure 4D, compare lane 2 with lane 4 for Substrate
*D19R4D18: D41). These products were resistant to degra-
dation by RNaseH2 added back after the ligation steps, in-
dicating that they did not contain rNMPs (Figure 4C, lane
7 for Substrate *D39R1D15: D55 and Figure 4D, lane 7 for
Substrate *D19R4D18: D41).
Specialized DNA polymerases support ribonucleotide exci-
sion repair also with DDX3X
Under similar conditions, we repeated the experiments sub-
stituting RNaseH2 with DDX3X. Starting from Substrate
*D39R1D15: D55 and using Pol  and Pol  under the same
conditions employed for RNaseH2, also with DDX3X a 55
nt repair product was generated in the presence of Fen-1
and DNA ligase 1 (Figure 5A, lane 6 for Pol  and lane 10
for Pol ), which was resistant to degradation by RNaseH2
added back after the ligation step (Figure 5A, lane 7 for Pol
 and lane 11 for Pol ). Also using Pol , we were able to
obtain a 55 nt repair product in the presence of Fen-1 and
DNA ligase 1 resistant to degradation by RNaseH2 added
back after the ligation step (Figure 5B, compare lane 6 with
lane 7).
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Figure 4. Different DNA polymerases support full ribonucleotide excision repair together with RNaseH2. (A) RER reactions in the presence of RNaseH2,
Pol  and dNTPs alone (lane 3), or with DNA ligase 1 and Fen-1 (lanes 4–5). Lane 5: re-digestion by RNaseH2 of the ligated products after heat inactivation
of the reaction. RER reactions in the presence of RNaseH2, Pol , PCNA and dNTPs (lane 6), or with added DNA ligase 1 and Fen-1 (lanes 7–8). Lane
8: re-digestion by RNaseH2 as in Lane 5. Lane 1: Substrate *D39R1D15: D55 alone. (B) RER reactions in the presence of RNaseH2, Pol , dNTPs, Fen-1
and DNA ligase 1 (lanes 2–5). RER reactions in the presence of RNaseH2, Pol , PCNA and dNTPs (lanes 6–8), DNA ligase 1 and Fen-1 (lanes 7–8).
Lanes 5 and 8: re-digestion by RNaseH2. Lane 1: Substrate *D19R4D18: D41 alone. (C) RER reactions in the presence of RNaseH2 (lanes 2–3), Pol ,
dNTPs (lanes 4–5), Fen-1 and DNA ligase 1 (lanes 6–7). Lanes 3, 5 and 7: re-digestion by RNaseH2. Lane 1: Substrate *D39R1D15: D55 alone. (D) Lane 1:
Substrate *D19R4D18: D41 alone. RER reactions in the presence of RNaseH2 (lanes 2–3), Pol , dNTPs (lanes 4–5), Fen-1 and DNA ligase 1 (lanes 6–7).
Lanes 3, 5 and 7: re-digestion by RNaseH2.
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Figure 5. A role of DDX3X in ribonucleotide excision repair. (A) RER reactions in the presence of DDX3X (lanes 2–3), Pol , dNTPs (lanes 4–5), Fen-1
and DNA ligase 1 (lanes 6–7). Lanes 3, 5, 7: re-digestion by RNaseH2 of the heat inactivated reactions. RER reactions in the presence of DDX3X, Pol ,
PCNA, dNTPs (lanes 8–9), Fen-1 and DNA ligase 1 (lanes 10–11). Lanes 9 and 11: re-digestion by RNaseH2. Lane 1: Substrate *D39R1D15: D55 alone.
(B) RER reactions in the presence of DDX3X (lanes 2–3), Pol , dNTPs (lanes 4–5), Fen-1 and DNA ligase 1 (lanes 6–7). Lanes 3, 5 and 7: re-digestion by
RNaseH2. Lane 1: Substrate *D39R1D15: D55 alone. (C) Western blot for DDX3X and -actin. L, molecular weight markers. NSC, non-silencing vector
control cells; shDDX3X, stable DDX3X-silenced cells. (D) Quantification of genomic rNMPs by the riboassay. NSC untreated cells signal was set as 1
fluorescence arbitrary unit. Different treatments were: untreated genomic DNA (–), genomic DNA treated with 1 U of E. coli RNaseH2 or with 50 nM
of human recombinant RNaseH2 (+). Data represent mean ± SEM of at least four independent experiments. (E) Western blot for vinculin, DDX3X and
RNaseH2A. L, molecular weight markers. siCNT, non-silencing smart-pool siRNAs; siDDX3X, DDX3X-silenced cells, siRH2A, RNaseH2A-silenced
cells. (F) Quantification of genomic rNMPs by the riboassay. siCNT (control) cells signal was set as 1 fluorescence arbitrary unit. As above, different
treatments were: untreated genomic DNA (–) and genomic DNA treated with 50 nM of human recombinant RNaseH2 (+). Data represent mean ± SEM
of at least four independent experiments.
Thus, our in vitro results indicated that both DDX3X and
RNaseH2 can initiate RER in cooperation with different
Pols.
Non-overlapping roles of DDX3X and RNaseH2 in ribonu-
cleotide excision repair
To assess whether DDX3X acts as an alternative RNaseH2-
like enzyme in cells, even in an RNaseH2 wild type genetic
background, we quantified the amount of genomic rNMPs
by a specific riboassay (see Materials and Methods), in cells
silenced for DDX3X. If our hypothesis is true, we expected
to see an accumulation of rNMPs in silenced cells compared
to the control. Stable DDX3X knockdown (KD) U2OS
cells were generated by lentiviral transduction of a specific
shRNA and silencing efficiency was assessed by Western
Blot (Figure 5C).
We found that the level of genomic rNMPs in stable
DDX3X KD cells was 3-fold higher than in the non-
silencing vector control (NSC) cell line after both E. coli
RNaseH2 and human RNaseH2 treatments with a P value
significance < 0.05 (Student’s t-test) (Figure 5D, compare
the fluorescence increase between NSC untreated and E.
coli RNaseH2- treated cells and shDDX3 untreated and E.
coli RNaseH2- treated cells). This result demonstrated that
DDX3X KD U2OS cells are more prone to accumulate rN-
MPs in their genome compared to not silenced cells, even
in the presence of a functional RNaseH2, suggesting that
in cells, DDX3X and RNaseH2 operate in alternative, non-
redundant RER pathways. To complement this approach
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we then silenced DDX3X and RNaseH2, alone or in com-
bination, also using siRNA technology. Silencing efficiency
was assessed by Western Blot (Figure 5E) and again we
show that DDX3X KD cells accumulate 3-times more ri-
bonucleotides compared to control in accordance with our
previous findings (Figure 5F). RNaseH2 silencing causes an
abundant ribonucleotides accumulation (Figure 5F) as pre-
viously published (25) while the silencing of both enzymes
did not result in an additive effect (Figure 5F). This result
could be either explained by the lower efficiency of silencing
in the double knockdowns samples or by the activation of
an alternative pathway since both RNaseH2 and DDX3X
were depleted (7,8).
DISCUSSION
According to the current models, error-free removal of rN-
MPs by RER absolutely relies on one key enzyme: the ri-
bonuclease RNaseH2, the only enzyme known so far to be
able to recognize and incise the DNA-RNA junction at the
5′ side of a single rNMP embedded into a double stranded
DNA. This elegant model, however, raises additional ques-
tions. For example, it has been shown so far that in the ab-
sence of RNaseH2, DNA topoisomerases can initiate and
aberrant, highly mutagenic rNMP removal reaction, lead-
ing to DNA deletions. Thus, it could be relevant for the
cell to have other less mutagenic, backup alternative mech-
anisms for rNMPs removal, which leads to the question as
to whether other enzymes besides RNaseH2 could initiate
RER. In addition, experimental evidence, also provided by
our group, suggest that repair Pols can incorporate rNMPs
(16,29). This raises the problem of which Pol might oper-
ate in cleaning the rNMPs incorporated as a consequence
of DNA repair, in RER of post-mitotic cells, such as neu-
rons for example, where replicative Pols  and ε are not ex-
pressed.
In the present manuscript, we offer a possible answer to
both these questions, by disclosing two absolutely novel, to
the best of our knowledge, findings: the existence of a sec-
ond RNaseH2-like enzyme in human cells, the RNA heli-
case DDX3X, and the ability of repair Pols  and  to allow
full RER reactions.
In our in vitro systems, DDX3X operated with an ap-
parent lower cutting efficiency than RNaseH2 (Figure 1B).
However, it should be noted that the calculated values only
represent a lower limit estimate of efficiency, assuming that
all DDX3X molecules present in the reaction were active
and the preparation homogeneous, which was only ap-
proximately correct (see mass spectrometry results, Supple-
mentary Tables S1 and S2). More importantly, DDX3X is
known to act as a scaffold for multiprotein complexes (9)
thus it is possible that auxiliary factors or post-translational
modifications might also modulate in vivo its efficiency in
this context.
Mass spectrometry analysis, combined with molecular
modeling-guided site-directed mutagenesis, confirmed that
the observed RNaseH2-like activity could be firmly at-
tributed to DDX3X. The closely related human RNA he-
licase DDX5 (43% identity, 60% similarity) failed to show
RNaseH2-like activity, also suggesting that it was peculiar
to DDX3X. In addition, our kinetic data show that the
RNaseH2-like activity of DDX3X did not require its RNA
helicase activity nor ATP. Moreover, they suggest that the
helicase vs. nuclease activities of DDX3X are regulated by
ATP, through the induction of different oligomeric states,
thus providing a possible mechanism for the modulation of
these two activities into the cell. Such a role of ATP as a
regulator of the stoichiometry of the interaction of DDX3X
and RNA is in agreement with the findings of Kim and My-
ong (32). The current model of helicase activity for DDX3X
implies that the enzyme acts as a multimer (trimer) whose
formation is triggered by ATP binding and that ATP hydrol-
ysis results its dissociation. Kim and Myong showed that
DDX3X undergoes a concentration-dependent oligomer-
ization, and ATP negatively impacted on the affinity of the
multimeric form for RNA, promoting its dissociation. In
monomeric form, the enzyme interacts differently with an
ssRNA molecule inducing a tight compaction of the nucleic
acid. Such a conformation, where the protein tightly wraps
around the nucleic acid strand tightly, would be the most
favorable also for sensing and processing a single rNMP
within a DNA strand. Our data show that DDX3X, dif-
ferently from RNaseH2, is very efficient in cutting a sin-
gle rNMP embedded within a ssDNA strand (Supplemen-
tary Figure S1h), consistent with this model. Thus, ATP
by inducing a different stoichiometry/affinity for the sub-
strate, shifts the equilibrium from a nuclease-competent to
a helicase-competent form.
The possibility shown here, to fully reconstitute RER re-
actions in vitro by various combinations of RNaseH2 and
DDX3X with at least three different Pols (Pol , pol  and
pol ), along with the observation that silencing DDX3X
causes rNMPs accumulation in the genome, even in a
RNaseH2 wild type background, suggests that RNaseH2
and DDX3X operate in a non-redundant fashion. Probably,
in cells the local availability of a particular Pol along with ei-
ther RNaseH2 or DDX3X, can be exploited by the different
alternative RER pathways. We are nonetheless well aware of
the fact that our in vitro system represents an oversimplifi-
cation of the in vivo situation, which need to be validated in
more physiological systems.
However, the potential relevance of our findings stretches
from showing the possibility of an efficient mechanism
of RER in non-replicating cells, to the suggestion that
RNaseH2-deficient cells might still, at least in part, coun-
teract rNMPs accumulation, but less efficiently. Indeed, ac-
cumulation of rNMPs in the genome above a certain thresh-
old, induces cellular stress also in the presence of a com-
pletely functional RNaseH2 (4). DDX3X seems crucial dur-
ing embryogenesis (13) while in adult cells some of its func-
tions could be compensated by other DEAD-box proteins
(38). However, loss of DDX3X correlates with increased
DNA damage accumulation (13). DDX3X (11) and Pols
 and  (39) are often overexpressed in solid tumors. Our
quantification of the DDX3X protein concentrations in sev-
eral tumor cell lines, revealed that many of them have levels
of DDX3X close to the concentrations used in our in vitro
systems (Supplementary Table S3). Thus, alternative RER-
pathways might contribute to the tolerance of high levels of
rNMPs in the genome by tumor cells.
As already mentioned, loss-of-function mutations of
RNaseH2 cause the neurodegenerative disease Aicardi-
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Goutieres Syndrome (28) through activation of innate im-
munity (40). DDX3X promotes innate immune responses
(41) and hypomorphic mutations of DDX3X have been
linked to neurological disorder and mental retardation (12).
Thus, our findings of its RNaseH2-like activity, may sug-
gest a role of this protein also in the pathogenesis of AGS,
through the differential processing of a specific subset of
DNA:RNA hybrids. In this context, it would be interest-
ing to assess the level of expression of DDX3X in cells from
AGS patients, as well as to evaluate their sensitivity towards
DDX3X silencing.
Overall, the results presented here challenge the current
RER model, significantly broadening the landscape of pos-
sible alternative mechanisms that can be used by human
cells to cope with the burden of misincorporated rNMPs.
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